Skip to main content

LeMaitre Vascular, Inc. (LMAT)

New York Stock Exchange Healthcare Medical - Instruments & SuppliesView data quality →
56.7Fair

ValueMarkers Composite Index

Top 62%#17,049 of 44,707
Overvalued

29% above intrinsic value ($89)

UndervaluedFair ValueOvervalued
Piotroski
7/9
Strong
Beneish
-2.13
Investigate
Altman
9.08
Safe
DCF Value
$89
Overvalued
ROIC
9.0%
Adequate
P/E
45.3
Growth
Updated: ·Source: Data sourced from SEC filings and institutional providers. Not financial advice.·Report data issue

LeMaitre Vascular, Inc. (LMAT) — VMCI valuation read

LeMaitre Vascular, Inc. (LMAT) carries a VMCI composite of 57/100, 7 points above the Healthcare sector median of 50. Among mid-cap names, that gap places LMAT in the top third on the five-pillar weighting (Value 35%, Quality 30%, Integrity 15%, Growth 12%, Risk 8%).

The LMAT insider tape has been silent for the past 30 days on Form 4. Where executives neither buy nor sell, the bull and bear cases lean harder on filings cadence and the next earnings line.

**Investor frame.** Value reads LMAT trades at 24.0x earnings, 33% above the Healthcare median of 18.0x, which compresses or extends through the 11.0x EV/EBITDA versus a Healthcare 12.0x. Quality: ROIC of 10.0% sits 0.0pp above the Healthcare median (10.0%). Risk: net debt to EBITDA of -0.1x leaves covenant headroom, the line to track on LeMaitre Vascular, Inc.'s next 10-Q.

LMAT fell 0.6% over the trailing 7 days, with a +5.5% read on a 30-day basis.

LeMaitre Vascular, Inc. designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. It offers angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; occlusion catheters that temporarily occlude the blood flow; perfusion catheters to perfuse the blood and other fluids into the vasculature; and thrombectomy catheters, which features a silicone balloon for removing thrombi in the venous system. The company also provides carotid shunts that temporarily shunt the blood to the brain during the removal of plaque from the carotid artery in a carotid endarterectomy surgery; and radiopaque tape, a medical-grade tape applied to the skin that enables interventionists to cross-refer between the inside and the outside of a patient's body, and allows them to locate tributaries or lesions beneath the skin. In addition, it offers valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and vascular grafts to bypass or replace diseased arteries. Further, the company provides vascular and cardiac patches, which are used for closure of vessels after surgical intervention; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.

CEO: George W. LeMaitre651 employeesUSwww.lemaitre.com

Top peers ranked by VM Score. Compare valuation, quality, and risk metrics across the sector.

Browse More

Key metrics explained

Definitions, formulas, and how ValueMarkers calculates each indicator used in LMAT’s VM Score.

Explore More

Compare Competitors

Weekly Stock Analysis - Free

5 undervalued stocks, fully modeled. Every Monday. No spam.

Cookie Preferences

We use cookies to analyze site usage and improve your experience. You can accept all, reject all, or customize your preferences.